GlassScriptPhysician profile
Marc S Schwartz
NPI 1275505570
$10,504.65
in general payments reported to CMS, 2019-2025
39 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,623 · 2020: $1,040 · 2021: $1,950 · 2022: $1,685 · 2023: $1,637 · 2024: $1,496 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,206.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,231.86 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,462.82 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $1,079.53 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $901.55 | 2019-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $519.87 | 2019-2022 | |
| Pfizer INC. | $417.10 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $401.60 | 2021-2025 | Verquvo |
| Baxter Healthcare | $387.04 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Abiomed | $318.63 | 2022-2025 | Impella |
| Janssen Pharmaceuticals, INC | $279.98 | 2019-2022 | |
| Boston Scientific Corporation | $265.30 | 2021-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Esperion Therapeutics, INC. | $233.47 | 2020-2025 | Nexletol |
| Abbott Laboratories | $233.26 | 2020-2024 | Confirm Rx, Aveir |
| Astrazeneca Pharmaceuticals LP | $213.99 | 2019-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $198.29 | 2019-2023 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $177.48 | 2022-2025 | Onpattro, Amvuttra |
| Kestra Medical Technology Services, INC. | $176.92 | 2024-2025 | Assure Wcd |
| Medtronic, INC. | $116.11 | 2023-2024 | Micra, Cobalt Dr Mri Surescan, Mycarelink |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.34 | 2019-2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $98.53 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $92.22 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Novo Nordisk INC | $90.20 | 2024-2025 | Rybelsus, Ozempic |
| Regeneron Healthcare Solutions, INC. | $84.26 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $70.42 | 2023-2024 | Inpefa |
| Amryt Pharma Holdings LTD | $45.58 | 2022-2023 | Juxtapid |
| Atricure, INC. | $39.69 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $35.15 | 2024 | Uptravi |
| Kiniksa Pharmaceuticals, LTD. | $33.92 | 2022-2023 | Arcalyst |
| Medtronic Vascular, INC. | $28.66 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $25.45 | 2020-2021 | |
| Cardiva Medical, INC. | $21.24 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Cvrx, INC. | $18.33 | 2024 | Barostim Neo System |
| Daiichi Sankyo INC. | $16.54 | 2024 | Injectafer |
| Tactile Systems Technology INC | $14.58 | 2021 | |
| Cmp Pharma, INC. | $14.42 | 2020 | |
| Chiesi USA, INC. | $14.42 | 2020 | |
| Agepha Pharma Fz LLC | $13.82 | 2025 | Lodoco |
| Avinger INC. | $13.55 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.